| PMC full text: | Cancer Genet. Author manuscript; available in PMC 2016 May 1. Published in final edited form as: Cancer Genet. 2015 May; 208(5): 206–214. Published online 2015 Feb 20. doi: 10.1016/j.cancergen.2015.02.008 |
Table 1
The cancer alteration rates for the described genes in clear cell Renal Cell Carcinoma, Chromophobe Renal cell Carcinoma, Papillary Renal Cell Carcinoma, Prostate Adenocarcinoma, and Urothelial Bladder Carcinoma were obtained from the indicated publications or from cBioportal website. The cancer alteration includes mutation, deletion, amplification and multiple alterations.
| Gene | Cancer Alteration rates in clear cell Renal Cell Carcinoma (TCGA) [20] | Cancer Alteration rates in Chromophobe Renal Cell Carcinoma [81] | Cancer Alteration rates in Papillary Renal Cell Carcinoma (TCGA) | Cancer Alteration rates in Prostate Adenocarcinoma | Cancer Alteration rates in Urothelial Bladder Carcinoma (TCGA) [82] |
|---|---|---|---|---|---|
| PBRM1 | 34.8% | 4.2% | 3.7% (provisional) | 0% (TCGA) | 10% |
| SETD2 | 13.7% | 3% | 6.8% (provisional) | 3.6% [83](Broad/Cornell) | 7.7% |
| BAP1 | 10.8% | 0% | 3.1% (provisional) | 0.9% [83](Broad/Cornell) | 4.6% |
| JARID1C /KDM5C | 6.7% | 3% | 1.2% (provisional) | 9.8% (Amplification) [84] (Michigan) | 1.5% |
| UTX /KDM6A | 1.2% | 0% | 4.3% (provisional) | 9.8% (Michigan) [84] | 26.1% |